Regulators throw up another hurdle to Roche’s $4.3B Spark acquisition as questions percolate over hemophilia market domination
Don’t look for Roche’s $4.3 billion Spark $ONCE buyout — announced 7 months ago — to close anytime in the very near future.
The UK Competition and Markets Authority just opened a 2-week public comment period on the tie-up, looking for some opinions on the pharma giant’s competitive position if the deal goes through.
In an announcement today the CMA remarked that they were soliciting remarks on “whether the creation of that situation may be expected to result, in a substantial lessening of competition within any market or markets in the United Kingdom for goods or services.”
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 77,100+ biopharma pros reading Endpoints daily — and it's free.